Fenoldopam mesylate and renal function in patients undergoing liver transplantation: A randomized, controlled pilot trial

G. Della Rocca, L. Pompei, M. G. Costa, C. Coccia, L. Scudeller, P. Di Marco, S. Monaco, P. Pietropaoli

Research output: Contribution to journalArticle

Abstract

To test the relative effects on serum creatinine (CRE), blood urea nitrogen (BUN), and urine output of small-dose dopamine and fenoldopam in patients undergoing liver transplantation, we randomized 43 patients to 1 of 2 continuous infusions over 48 h, starting with anesthesia induction: fenoldopam, 0.1 μg·kg -1·min -1 or dopamine, 2 μg·kg -1·min -1. We used predetermined hemodynamic and intravascular volume goals (intrathoracic blood volume index 800-1000 mL/m 2, extravascular lung water index 1 mL·kg -1·h -1. At postoperative day 3, the median CRE increase was 0.2 mg/dL (interquartile range [IQR] -0.2-0.5) with fenoldopam and 0.5 mg/dL (IQR 0.3-0.9, P = 0.004) in the dopamine group. The BUN increase was median 2 mg/dL (IQR -2-8) versus 8.5 mg/dL (IQR 5-12, P = 0.01), respectively, with fenoldopam versus dopamine. Urine output was similar; however, significantly fewer fenoldopam patients required furosemide compared with dopamine patients (median 1 [IQR 0-3] versus 3 [IQR 2-4], respectively, P = 0.003). The hemodynamic effects of dopamine and fenoldopam were similar. Compared with dopamine, in the setting of liver transplantation, fenoldopam is associated with better CRE and BUN values.

Original languageEnglish
Pages (from-to)1604-1609
Number of pages6
JournalAnesthesia and Analgesia
Volume99
Issue number6
DOIs
Publication statusPublished - Dec 2004

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Fenoldopam mesylate and renal function in patients undergoing liver transplantation: A randomized, controlled pilot trial'. Together they form a unique fingerprint.

Cite this